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TaqManTM genotyping assays are widely used to genotype CYP2D6, which encodes a
major drug metabolizing enzyme. Assay design for CYP2D6 can be challenging owing to
the presence of two pseudogenes, CYP2D7 and CYP2D8, structural and copy number
variation and numerous single nucleotide polymorphisms (SNPs) some of which reflect
the wild-type sequence of the CYP2D7 pseudogene. The aim of this study was to
identify the mechanism causing false-positive CYP2D6∗15 calls and remediate those
by redesigning and validating alternative TaqMan genotype assays. Among 13,866 DNA
samples genotyped by the CompanionDx® lab on the OpenArray platform, 70 samples
were identified as heterozygotes for 137Tins, the key SNP of CYP2D6∗15. However,
only 15 samples were confirmed when tested with the Luminex xTAG CYP2D6 Kit and
sequencing of CYP2D6-specific long range (XL)-PCR products. Genotype and gene
resequencing of CYP2D6 and CYP2D7-specific XL-PCR products revealed a CC>GT
dinucleotide SNP in exon 1 of CYP2D7 that reverts the sequence to CYP2D6 and
allows a TaqMan assay PCR primer to bind. Because CYP2D7 also carries a Tins, a
false-positive mutation signal is generated. This CYP2D7 SNP was also responsible
for generating false-positive signals for rs769258 (CYP2D6∗35) which is also located
in exon 1. Although alternative CYP2D6∗15 and ∗35 assays resolved the issue, we
discovered a novel CYP2D6∗15 subvariant in one sample that carries additional SNPs
preventing detection with the alternate assay. The frequency of CYP2D6∗15 was 0.1%
in this ethnically diverse U.S. population sample. In addition, we also discovered linkage
between the CYP2D7 CC>GT dinucleotide SNP and the 77G>A (rs28371696) SNP of
CYP2D6∗43. The frequency of this tentatively functional allele was 0.2%. Taken together,
these findings emphasize that regardless of how careful genotyping assays are designed
and evaluated before being commercially marketed, rare or unknown SNPs underneath
primer and/or probe regions can impact the performance of PCR-based genotype
assays, including TaqMan. Regardless of the test platform used, it is prudent to confirm
rare allele calls by an independent method.
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INTRODUCTION
TaqMan genotyping assays are widely used within research
and clinical testing laboratories. Due to the availability of pre-
designed assays, genotyping using this technology is relatively
straight forward, allows customization of individual assays
into panels (such as the OpenArray platform, Thermo Fisher
Scientific, Waltham, MA) and is automatable (Mein et al.,
2000; Ranade et al., 2001; Johnson et al., 2012; Fedick et al.,
2013). Owing to these advantages, TaqMan technology is
widely employed for CYP2D6 genotype analysis. Among all
drug metabolizing enzymes, CYP2D6 is probably the most
structurally and genotypically complex, and extensively studied
gene (Zanger et al., 2004, 2008; Ingelman-Sundberg, 2005;
Ingelman-Sundberg et al., 2007; Ingelman-Sundberg and Sim,
2010; Teh and Bertilsson, 2012; Zanger and Schwab, 2013).
It metabolizes numerous clinically-used drugs, including many
antidepressants, antipsychotics, and opioids (Zhou, 2009a,b).
Pre-emptive CYP2D6 genotype testing is increasingly used to
guide therapy (Dunnenberger et al., 2015), or used to explain
adverse drug reactions or treatment failure after treatment
initiation (Zhou et al., 2015).
Assay design for CYP2D6, however, is arduous due to the
presence of two pseudogenes, CYP2D7 and CYP2D8, within
the gene locus, structural and copy number variation and the
presence of numerous single nucleotide polymorphisms and
insertion/deletion variations (collectively referred here as SNPs;
Gaedigk, 2013). Hence, it is challenging to identify genome-
unique regions in the vicinity of target SNPs to design robust
TaqMan genotyping assays. SNPs located underneath a primer
or TaqMan probe binding site can affect an assay’s performance.
As recently reported, SNPs within the amplicon can also impact
assay performance (Gaedigk et al., 2015a).
Although most test panels include only the SNPs defining
the most common CYP2D6 alleles, others routinely test for
rare or extremely rare alleles, including CYP2D6∗15 (http://
www.ncbi.nlm.nih.gov/gtr/). This allele is characterized by
a nucleotide insertion in exon 1 (137Tins) that causes a
frameshift and leads to premature translation termination.
Of note, per definition the CYP2D7 gene also carries two
Ts at the homologous position, which is a hallmark feature
rendering this pseudogene nonfunctional. CYP2D6∗15 was first
described in a German population (Sachse et al., 1996), but
it has not been detected in other European populations.
Although data for this allele are sparse, it has been reported
in Brazilians of European ancestry (Kohlrausch et al., 2009),
Lengua Native Americans of Paraguay (Bailliet et al., 2007) and
a Mexican population (Alcazar-González et al., 2013), but not
in other world populations. Based on the available literature,
this nonfunctional allele has an extremely low frequency
of <0.5%. A summary of allele frequencies can be found in
Clinical Pharmacogenetics Implementation Consortium (CPIC)
guidelines (Hicks et al., 2013, 2015; Crews et al., 2014)
or via the web at http://www.pharmgkb.org/download.action?
filename=CYP2D6_Frequency_Table_and_Legend_R3.pdf. Due
to the rarity of certain alleles, it is therefore difficult to get hold
of gDNA reference material for assay development and quality
control. Consequently, it is important to verify assay results to
avoid reporting false-positive results that may cause wrongful
genotype assignments and may lead to inaccurate predictions of
a subject’s phenotype status.
In contrast to CYP2D6∗15, the CYP2D6∗35 allele is more
commonly observed. The latter can be identified by a SNP
that is also located in exon 1 and represents a “key” allelic
feature for identification (31G>A, rs769258, V11M). This SNP
was first reported in 1997 (Marez et al., 1997) and is most
commonly noted in Europeans with an average frequency of
6%. Its frequency is much lower or absent in other populations.
CYP2D6∗35 is often not tested for because it is deemed fully
functional. In the absence of testing for this variant, a CYP2D6∗1
or ∗2 will be assigned by “default” depending on test design.
TaqMan assays were extensively validated by CompanionDx R©
using Coriell DNA and hundreds of DNA samples which
were confirmed by orthogonal methods such as the Luminex
xTAG CYP2D6 platform and Sanger sequencing. No false-
negative calls were detected during these validation efforts.
Subsequently, however, we identified samples testing positive for
the CYP2D6∗15 allele (137Tins) in a large cohort of subjects
residing in the U.S. Verification of the results with alternative
methods uncovered false-positive CYP2D6∗15 calls.
The aim of this study was to identify the factors responsible
for the false-positive genotype calls and to remediate those by
redesigning and validating alternative TaqMan genotype assays.
MATERIALS AND METHODS
Subjects and samples
DNA was isolated from buccal swab samples of a large, ethnically
diverse U.S. population of 13,866 consecutive subjects (n =
27, 740 alleles). Samples from 20 subjects who gave written
informed consent and had positive TaqMan CYP2D6∗15 calls,
were selected for follow-up studies (Table 1). Due to limited
amounts of gDNA, Whole Genome Amplification (WGA) was
performed using 15 ng of gDNA and the GenomiPhi DNA
Amplification kit (GE Healthcare Life Sciences, Pittsburgh, PA
USA) as recommended by the supplier. WGA-DNA was diluted
1:25-fold for subsequent testing of TaqMan genotype assay
performance.
NA17128 was obtained from the Coriell Institute for Medical
Research (Camden, NJ). Two de-identified DNA samples from a
repository maintained at Children’s Mercy (PGx-A and B) served
as controls. The use of repository samples was approved by the
Institutional Review Board of Children’s Mercy Kansas City.
TaqMan genotyping
Initial genotype analysis of the 13,866 samples was performed
with commercially available TaqMan assays using the OpenArray
platform on a QuantStudio 12K Flex instrument (Thermo
Fisher Scientific; formerly Life Technologies, Grand Island,
NY). The OpenArray included assays testing of the following
SNPs: −1584C>G (rs1080985), 100C>T (rs1065852), 124G>A
(rs5030862), 137Tins (rs72549357), 883G>C (rs201377835),
1023C>T (rs28371706), 1707T>del (rs5030655), 1758G>T/A
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TABLE 1 | Summary of CYP2D6*15 genotyping and sequencing results with the initial and alternate TaqMan genotyping assays.









1 Unknown *15 het *15 het No signal *2A/*15 No call CC *15 het *15 het *15 het No signal
2 African
American
*15 het wt *15 mut *1/*17 *1/*17 CC/GT wt wt wt No signal
3 Unknown *15 het wt *15 mut *1/*2B *1/*2 CC/GT wt wt wt No signal
4 Caucasian *15 het wt *15 mut *1/*4, dupc *1/*4, dupc CC/GT wt wt wt No signal
5 Hispanic *15 het wt *15 mut *1/*1 *1/*1 CC/GT wt No gDNA wt No signal
6 Unknown *15 het wt *15 mut *1/*2Dh *1/*29 GT wt wt wt No signal
7f Caucasian *15 het wt no result *1/*2, dupc *1/*2, dupc no result wt no result no result No result
8 African
American
*15 het wt *15 mut *1/*17 *1/*17 CC/GT wt wt wt No signal
9 Hispanic *15 het wt *15 mut *1/*2, dupc *1/*2, dupc CC/GT wt No gDNA wt No signal
10 African
American
*15 het wt *15 mut *1/*17 *1/*17 CC/GT wt No gDNA wt No Signal
11 Caucasian *15 het *15 het No signal *2A/*15 *2/*15 CCe *15 het No gDNA *15 het No Signal
12 African
American
*15 het wt *15 mut *1/*17, dupc No call CC/GTe wt No gDNA wt No signal
13g Caucasian *15 het *15 hetd No signal *4/*15 *4/*15 CCe *15 hetd wt wtd No signal
14 Caucasian *15 het *15 het No signal *15/*41 *15/*41 CC *15 het *15 het *15 het No signal
15 African
American
*15 het wt *15 mut *2A/*17 *2/*17 CC/GTe wt wt wt No signal
16 Hispanic *15 het wt *15 mut *1/*17 *1/*17 CC/GT wt wt wt No signal
17 African
American
*15 het wt *15 mut *1/*1 *1/*1 CC/GT wt No gDNA wt No signal
18 Caucasian *15 het wt *15 mut *1/*1 *1/*1 CC/GTe wt No gDNA wt No signal
19 African
American
*15 het wt *15 mut *1/*41 *1/*41 CC/GTe wt No gDNA wt No signal
20 African
American
*15 het wt *15 mut *1/*17 *1/*17 CC/GT wt No gDNA wt No signal
TaqMan genotyping TaqMan
NA17128i *15 het wt *15 mut *1/*1 n/d CC/GTe wt wt wt No signal
PGx-Ai wt wt No signal *2/*41 n/d CC wt wt wt No signal
PGx-Bi wt wt No signal *4/*6 n/d CC wt wt wt No signal
a initial and alternate assay IDs are C__32407245_40 and C__32407245_60, respectively.
bOpenArray genotyping results were obtained with the original CYP2D6*15 TaqMan assay.
cSample was positive for a duplication event, but platform does determine on which allele the duplication is located.
dThe result with the alternate TaqMan genotyping assay is discordant.
eCYP2D7 variation identified by sequencing and confirmed by HRM.
fSample did not yielded results for all follow-up studies.
gNovel CYP2D6*15 variant.
hCYP2D6*29 could not be assigned with the TaqMan assay set used in this analysis. All samples with a red “*1” were false-positive for *15 and also positive for 77G>A suggesting the
presence of a CYP2D6*43 (see Suppl Table 1).
iGenotyped using TaqMan genotyping assays in 96-well format. het, heterozygous; mut, homozygous for variant; no signal, no fluorescent signal was detected indicating that no
amplicon has been generated; n/d, not determined.
Note that the CYP2D7 CC>GT variation is inventoried by dbSNP under rs386821512 and annotated as GG>CA on the forward genome strand.
(rs5030865), 1846G>A (rs3892097), 2549delA (rs35742686),
2613_2615delAGA (rs5030656), 2850C>T (rs1694700,
2935A>C (rs5030867), 2988G>A (rs28371725), and 4180G>C
(rs1135840). CYP2D6∗15 (137Tins) was detected using TaqMan
assay ID C__32407245_40. Follow-up TaqMan genotyping for
CYP2D6∗15 (137Tins; assay ID C__32407245_40) and ∗35 (31G
>A, rs769258; assay ID C_27102444_80) was performed on a
QuantStudio 12K Flex instrument using 96-well plates and the
TaqMan Genotyping Mastermix Mix (Thermo Fisher Scientific-
Life Technologies, Grand Island, NY) as recommended by the
manufacturer.
Follow up studies were also conducted with alternative assays
for CYP2D6∗15 and CYP2D6∗35 (to be commercialized with
assay IDs C__32407245_60 and C_27102444_F0, respectively).
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The PCR primers in these redesigned assays were moved to
alternate binding sites flanking each mutation, which contained
nucleotide differences between CYP2D6 and CYP2D7 sequences
to drive CYP2D6-specific amplification and avoid nonspecific
amplification of CYP2D7 caused by primer overlap with
the CYP2D7 rs386821512 SNP in the original assays. Assay
performance was tested on gDNA, WGA-DNA and CYP2D6
and CYP2D7 XL-PCR templates using the 96-well format as
described below. In addition, a custom TaqMan SNP genotyping
assay to detect 77G>A, which is part of the CYP2D6∗43 and ∗46
haplotypes, was run on CYP2D6 XL-PCR templates.
Long-range (XL)-PCR was performed to specifically amplify
the CYP2D6 and CYP2D7 genes in their entirety. Briefly,
CYP2D6-specific, 6.6 or 6.7 kb long fragments were generated
with primers pairs forward 5′ GGCTCCAAGCATGGCAGCTGC
and reverse 5′CGACTGAGCCCTGGGAGGTAGGTAG and
forward 5′ TCACCCCCAGCGGACTTATCAACC and reverse
5′CGACTGAGCCCTGGGAGGTAGGTAG, respectively,
essentially as previously described; this fragment is referred to as
fragment A in previous reports (Gaedigk et al., 2007, 2015b). The
6.6 kb-long fragment was used for sequence-based confirmation
of CYP2D6∗15 TaqMan assay results; the 6.7 kb long fragment
A, which amplifies more robustly, was generated for all other
follow-up studies and evaluation of the alternate TaqMan
genotyping assays. The 4.4 kb long fragment for CYP2D7 was
generated with primers 5′ TCCGACCAGGCCTTTCTACCAC
and 5′ CACCAGAAAGCTGACGACACGAGA. An 8µl reaction
contained 15 ng gDNA, 5% DMSO, 500 nM of each primer, and a
1X final concentration of Kapa Long Range HotStart Master Mix
(Kapa Biosystems, Wilmington, MA). PCR cycling parameters
included an initial denaturation for 3min at 94◦C, followed by 35
cycles of denaturation at 94◦C for 20 s, annealing at 68◦C for 30 s
and extension at 68◦C for 7min. To assure CYP2D6 or CYP2D7
amplicon generation, 2µl aliquots were analyzed by agarose
gel electrophoresis. PCR fragments were diluted 2000-fold with
10mM Tris pH 7 to serve as templates in TaqMan and High
Resolution Melt (HRM) assays.
Luminex genotyping
To confirm CYP2D6∗15-positive results, genotyping was
conducted on the FDA-cleared Luminex platform with the xTAG
CYP2D6 Kit V3 (Luminex Corporation, Austin, TX) following
the provided protocol. Briefly, the assay incorporates multiple
PCR reactions and allele-specific primer extension assays. All
assays were read on the Luminex LX200 device using IS 3.1.971
software and the data were analyzed by xTAG CYP2D6V3 data
analysis software version 1.22. Additional assay details including
the alleles tested can be found at the company’s website. This
platform was chosen because it utilizes a different SNP detection
technology than TaqMan.
DNA sequencing
For confirmation, a 6.6 kb long fragment A was generated from
66 of the 70 samples that were found positive for CYP2D6∗15 and
partially sequenced over the exon 1 region harboring the 137Tins.
CYP2D6 exon 1 was amplified using the predesigned primer
pairs forward 5′ATGTATAAATGCCCTTCTCCAGGAA and
reverse 5′GCAGGTTCACTCACAGCAGAG (Hs00225801_CE,
Thermo Fisher Scientific). PCR products were sequenced
using the BigDye Direct Cycle Sequencing Kit (Life
Technologies) and a 3730xl DNA Analyzer instrument (Life
Technologies).
The exon 1 region of a CYP2D7-specific XL-PCR product
from selected samples was also sequenced with BigDye chemistry
on a 3730xl DNA Analyzer. The CYP2D6 and CYP2D7 genes of
NA17128 were sequenced in their entirety.
DNA sequences were aligned to M33388 and AY545216
(reference sequences for CYP2D6) and to four unique
CYP2D7 sequences: M33387, ENS00000205702 (corresponding
to ENS00000612115 and NC_000022.11 of GRCh38.p2),
ENS00000263181 and ENS00000278088. There is no recognized
reference sequence for CYP2D7 at this time; ENS00000205702
was set as a reference because this sequence represents CYP2D7
in GRCh38.
High Resolution Melt (HRM) analysis
To facilitate screening of CYP2D7 rs386821512 (CC>GT;
positions −1 and −2 in respect to the ATG start codon;
GRCh38 42144465:42144466) a HRM assay was developed.
Briefly, a 164 bp amplicon was generated with primers
forward 5′ GTCACGCGCTCGGTGTGCTGAG and reverse
5′ CCACCAGGAGCAGGAAGATTGCCAC. Six µl reactions
contained 400 nM of each primer, 2.5mM MgCl2, and 0.6µl of
1:2000-fold diluted XL-PCR amplicon. The reaction was cycled
at an initial denaturation of 95◦C for 3min, followed by 30
cycles of denaturation at 95◦C for 5 s, annealing at 72◦C for
10 s and extension at 72◦C for 20 s. Melt curve analysis was
performed using the Eco Real-Time PCR System (Illumina, San
Diego, CA). Note that the primers used for this assay are not
CYP2D7-specific and, therefore, this assay must be performed on
a CYP2D7 XL-PCR template and not gDNA. NA17128 served as
positive control.
CYP2D6 Nomenclature
Allele designations throughout the manuscript are according to
those defined by the Human Cytochrome P450 (CYP) Allele
Nomenclature Database (Sim and Ingelman-Sundberg, 2013) at
http://www.cypalleles.ki.se/.
RESULTS
Among a large, diverse U.S. population of 13,866 samples, 70
samples (0.5%) initially tested positive for CYP2D6∗15 when
genotyped on the OpenArray platform (Suppl Table 1). Of those,
19 self-identified as Caucasian, 34 as African American, 7 as
Hispanic, 1 as Asian and 9 were of unknown ethnicity.
To confirm the presence of this relatively rare nonfunctional
allele, all 70 samples which returned positive results for
CYP2D6∗15 were genotyped with the Luminex xTAG system.
For 66 samples, the CYP2D6-specific 6.6 kb long XL-PCR
product was generated and the exon 1 region sequenced; the
remaining samples failed to produce the amplicon. Fifteen
samples were confirmed CYP2D6∗15-positive; among those were
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FIGURE 1 | Interference of CYP2D7 variation on CYP2D6*15 and *35 TaqMan genotype assay results. (A) Shows the exon 1 region of CYP2D6 and the
CYP2D7 pseudogene. Sequence differences at the −1 and −2 positions are highlighted in green and the ATG translation start codon is underlined. CYP2D7 carries a
CC at positions −1 and −2 while CYP2D6 has GT. This difference was employed for primer design for the initial CYP2D6*15 TaqMan genotyping assay. SNPs defining
allelic variants are shown in red; nucleotide positions are as indicated. The primer location is provided by the arrow. An “X” indicates that the primer does not generate
PCR product. (B) Details the mechanism by which false-positive assay results are generated. The first example shows a correct CYP2D6*15 call; the TaqMan primer
only binds to CYP2D6. In the second example, one CYP2D7 allele carries GT allowing primer binding and PCR product amplification. Since the CYP2D7 derived
amplicon has the T-insertion and 31A, the assay yields a false-positive results for CYP2D6*15 and *35. In the third example, CYP2D6*15 will also be false-positive.
Regarding 31G>A, fluorescent signals will be generated from the variant CYP2D7 allele as well as the CYP2D6*35 allele which may lead to a shift in cluster position.
11 Caucasians, one Asian and three of unknown ethnicity. Fifty-
one samples were negative for CYP2D6∗15 by sequencing and
Luminex assay (Table 1 and Suppl Table 1).
A Coriell sample (NA17128) was independently observed
by one of the authors to be heterozygous for CYP2D6∗15
when genotyped with TaqMan from gDNA. These observations
led us to hypothesize that nonspecific amplification from the
CYP2D7 pseudogene may cause these miscalls. To explore
this, 20 of the 70 samples and NA17128 were selected for
further analysis along with two samples, PGx-A and PGx-B,
that were previously genotyped as negative for CYP2D6∗15
and ∗35 (Table 1). Sequence analysis of the CYP2D7 region
of interest revealed CC>GT SNPs in exon 1 of CYP2D7 at
positions −1 and −2 relative to the ATG start codon in false-
positives and NA17128 (Figure 1A). This sequence variation was
also present in all other false-positive samples as subsequently
determined by HRM analysis that was performed on a XL-
PCR template encompassing the CYP2D7 gene (Figure 2). As
illustrated in Figure 1B, the CYP2D7 CC>GT SNPs revert the
sequence to CYP2D6 and thereby allowed one of the CYP2D6∗15
TaqMan genotyping assay PCR primers to bind and support
the generation of an amplicon from CYP2D7. Because CYP2D7
also carries an additional T in exon 1 (the CYP2D6 137Tins in
fact corresponds to the CYP2D7 reference sequence), a mutation
signal is generated, triggering the false-positive CYP2D6∗15 calls.
Interestingly, NA17128 was also heterozygous for CYP2D6∗35
(31G>A), but lacked other SNPs such as −1584C>G
(rs1080985), 2850C>T (rs16947), or 4180G>C (rs1135840)
known to be linked with 31G>A (Gaedigk et al., 2003). We
therefore suspected that the CYP2D7 CC>GT variation may
also interfere with the CYP2D6∗35 genotyping TaqMan assay,
resulting in false-positive calls as well given that the CYP2D6∗15
and ∗35 assays share a primer binding site that overlies the
dinucleotide change. Indeed, all samples with a false-positive
CYP2D6∗15 call presented as false-positive for CYP2D6∗35
when genotyped on gDNA or WGA-DNA and were negative
when genotyping was performed on CYP2D6-specific XL-PCR
amplicons suggesting that the CYP2D7 CC>GT dinucleotide
SNP is indeed the underlying cause for the false-positive
results.
Frontiers in Pharmacology | www.frontiersin.org 5 January 2016 | Volume 6 | Article 312
Riffel et al. CYP2D7 Interferece with TaqMan CYP2D6∗15 and ∗35 Genotyping
FIGURE 2 | High Resolution Melt (HRM) assay detecting variation on
CYP2D7-specific XL-PCR template. Blue indicates wt, green heterozygous
and red variant.
These conclusions were further corroborated by running both
TaqMan genotyping assays on CYP2D7-specific template. As
expected, those carrying CC>GT produced a “homozygous”
signal (only the variant CYP2D7 allele amplified, mimicking
homozygosity) while those not having CC>GT did not produce
a fluorescence signal.
To address these false-positive calls, alternate CYP2D6∗15
and ∗35 assays were designed and evaluated on CYP2D6 and
CYP2D6 XL-PCR templates, gDNA and WGA-DNA. Figure 3A
shows a cluster plot of selected samples for the initial CYP2D6∗15
assay. As can be seen, the samples identified as false-positives,
although on a slightly different trajectory, cluster with true
heterozygotes. Since CYP2D6∗15 is an extremely rare allele, there
are typically no, or perhaps single, positive samples in a run
besides a heterozygous control sample, making it impossible to
distinguish true from false-positives. As shown in Figure 3B, the
alternate assay was specific, i.e., the samples that were initially
false-positive (shown boxed in Figure 3A) now clustered with
wild-type control samples. Furthermore, the alternate assay did
not produce any fluorescent signals when CYP2D7 XL-PCR was
used as template, indicating amplification was not supported
from CYP2D7, including the variants that carry CC>GT (data
not shown). Similar results were obtained for the initial and
alternate CYP2D6∗35 assays, respectively (Figure 4). The false-
positive samples, however, formed a more distinct cluster when
run with the initial assay due to extra VIC signal contributed by
amplification of the CYP2D6 allele. Since CYP2D6∗35 is a more
common allele, false-positives may be easier to provisionally
identify compared to CYP2D6∗15 false-positives; albeit in other
experiments run with gDNAs this pattern has been less obvious
(data not shown). When run with the alternate assay, the
false-positive samples cluster unequivocally with the wild-type
controls. Genotyping and sequencing results for all 70 samples
as well as NA17128 and two control samples are summarized in
Table 1 and Suppl Table 1.
Sequencing of the CYP2D6 gene in NA17128 revealed SNPs at
77G>A (rs28371696; heterozygous), 310G>T (rs28371699,
homozygous), 843T>G, (heterozygous), and 1067T>G
FIGURE 3 | TaqMan scatter plots generated with the initial (A) and
alternate (B) CYP2D6*15 TaqMan genotyping assay for false-positive
and true positive samples. Profiles shown were generated on WGA-DNA.
Boxed samples are false-positives with the initial assay (A) that have been
resolved with the alternate TaqMan genotyping assay. (B) Black dot in symbol
indicates sample 13 carrying the novel CYP2D6*15var. This subject was
false-negative with the alternate CYP2D6*15 genotyping assay.
(heterozygous), which is consistent with a CYP2D6∗1var2/∗43
genotype (∗1var2 is a ∗1 subvariant we have recently observed in
a trio and described elsewhere (Twist et al., in press). Subsequent
TaqMan genotyping of our study cohort revealed that 77G>A
was present in 14 samples (Table 1 and Suppl Table 1 and Suppl
Figure 1). XL-PCR sequence data also revealed the presence of
77G>A (CYP2D6∗43) in most subjects initially thought to have
a CYP2D6∗1 allele.
Three of the four sequencing-confirmed samples were also
correctly identified with the alternative CYP2D6∗15 assay, while
all false-negative samples returned wild-type calls. Sample #13,
however, which was initially genotyped as CYP2D6∗4/∗15
(Table 1 and Suppl Table 1) and confirmed by Luminex xTAG
genotyping, was not identified by the alternate CYP2D6∗15
TaqMan assay to have the 137Tins. In addition to the CYP2D6∗15
137Tins XL-PCR sequencing of the exon 1 region also revealed
heterozygosity for 77G>A, a SNP that is part of the CYP2D6∗43
allele definition, and two novel exon 1 SNPs, 102A>G and
108C>T. As shown in Suppl Figure 1, 102A>G and 108C>T
interfere with one of the alternate CYP2D6∗15 TaqMan assay
primers suggesting that these SNPs as well as 77G>A are on the
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FIGURE 4 | TaqMan amplification profiles generated with the initial (A)
and alternate (B) CYP2D6*35 TaqMan genotyping assay for
false-positive and true positive samples. Profiles shown were generated
on WGA-DNA. Boxed samples are false-positives (A) that have been resolved
with the alternate TaqMan genotyping assay (B).
same chromosome as 137Tins forming a novel CYP2D6∗15var
haplotype.
We did not find any evidence that the use of WGA-DNA
impacted assay results. Specifically, the redesigned CYP2D6∗15
and ∗35 assays were performed on a subset of samples on both
gDNA andWGA-DNA. Furthermore, there were no inconsistent
findings between WGA-DNA-derived TaqMan assay results and
any other results obtained on gDNA including genotype analysis
on the Luminex platform or genotyping or sequencing of XL-
PCR products that would have indicated erroneous results using
WGA-DNA.
Lastly, sequence analysis of the CYP2D7 gene of NA17128 and
comparison to four unique CYP2D7 sequences (Suppl Table 2)
identified CC>GT SNV at positions −1 and −2 (in relation to
the ATG start codon), heterozygosity for seven SNPs that were
not observed in any of the other CYP2D7 sequences, as well as a
number of SNPs that are present in one or more of the CYP2D7
sequences it was compared to.
DISCUSSION
TaqMan assays are carefully designed and evaluated before
commercial marketing. However, rare or unknown SNPs
located underneath primer and/or probe regions can impact
the performance of many genotype assays, including TaqMan
(Gaedigk et al., 2015a,b). We have previously also shown that a
small cluster of SNPs found within the PCR amplicon, and not
under the primer/probe regions, can negatively impact TaqMan
genotype assay performance in certain instances (Gaedigk et al.,
2015a).
Here we report for the first time that a SNP in the highly
similar CYP2D7 pseudogene interferes with a CYP2D6 TaqMan
genotype assay. In the cases presented, the underlying cause of
the false-positive results did not reside within the interrogated
gene, but it’s near identicalCYP2D7 pseudogene. The high degree
of sequence identity between CYP2D6 and CYP2D7 makes it
extremely difficult to find regions that are gene-specific that fulfill
other TaqMan assay requirements including amplicon size. The
region immediately upstream of the ATG start codon differs
between the two genes by two consecutive nucleotides when
available genomic sequences are compared (CYP2D6 has GT and
CYP2D7 has CC) making this region a good target for primer
design. A rare dinucleotide SNP on CYP2D7, however, converted
the sequence to CYP2D6, allowing primer binding as outlined
in Figure 1. Consequently, a PCR product was formed from the
intended CYP2D6 target and from the variant CYP2D7 allele,
generating pseudo-heterozygosity. Since CYP2D7 carries an
additional T in exon 1 (corresponding to the CYP2D6∗15 variant
sequence), a mutation signal will be generated by the TaqMan
fluorogenic probe off the CYP2D7 amplification product; as the
fluorescent signal is produced from two CYP2D6 alleles and one
CYP2D7 allele, such samples possess a slightly different trajectory
and position in the cluster plot (Figure 3A for CYP2D6∗15 and
Figure 4A for CYP2D6∗35). Similar observations are made when
samples carry a gene duplication, e.g., CYP2D6∗1/∗4x2, in which
signals are also derived from three loci.
Currently, there are >2000 variant annotations for the
CYP2D7 pseudogene, many with unknown frequencies or minor
allele frequencies (MAF)<0.1% (ENSEMBL, accessed 8-8-2015).
Among those is the CC>GT variation which is inventoried by
dbSNP under rs386821512 with no population or frequency data.
However, this dinucleotide variant appears to be represented in
the NCBI dbSNP database as two recently characterized SNPs:
a C>G SNP at position −1 (rs556798398) and a C>T SNP
at position −2 (rs538594407). These SNPs were identified in
the 1000 Genomes (1000 g) project (Abecasis et al., 2012) at
an overall population frequency of 0.42% each; a review of the
1000 g phase 3, May 2013 data indicated that both SNPs are
found in the same 21 individuals. Similarly, all five samples that
were sequenced in our study contained CYP2D7 CC>GT and
HRM patterns of the remaining samples were consistent with the
samples carrying CC>GT.
The numerous CYP2D7 sequence variations annotated in
GenBank and ENSEMBL make it almost impossible to negotiate
CYP2D7 variation when designing CYP2D6 genotyping assays.
Moreover, gDNA samples carrying rare alleles are often not
available to validate assay performance, i.e., validation that the
assay not only detects the allele of interest in heterozygous
and homozygous samples, but that no other variant(s) impact
the assay’s performance. It is therefore prudent to confirm the
presence of rare SNPs with a reference method to validate
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assay performance and avoid reporting false-positive results.
TaqMan genotyping assays are extensively tested before being
commercially available; however, in situations such as the one
described here and reported previously (Gaedigk et al., 2015a,b),
rare SNPs, or SNPs in certain genotype constellations, can cause
false results that may potentially lead to incorrect phenotype
prediction and impact clinical decision making for a patient.
The present work is also the first report establishing
the presence of CYP2D6∗15 on a large population cohort.
Although this allele was among the first described and
designated in CYP2D6, there are sparse data regarding its
population distribution and frequency (http://www.pharmgkb.
org/download.action?filename=CYP2D6_Frequency_Table_and
_Legend_R3.pdf). In our diverse U.S. population, we identified
only 15 CYP2D6∗15 carriers, which corresponds to a prevalence
of 0.1% and an allele frequency of 0.05%. Among those, 11
subjects self-identified as Caucasians, one as Asian and three
were of unknown ethnicity.
Among the 55 false-positive samples which were confirmed by
Luminex genotyping and XL-PCR sequencing, the majority were
African American (n = 34), followed by Caucasians (n = 8),
Hispanics (n = 7) and those with unknown ethnicity (n = 6);
NA17128 is also Caucasian. Although there are no frequency data
for rs386821512 (CC>GT) per the dbSNP database (accessed 9-
30-2015), the MAF data for the apparently linked rs556798398
(C>G) and rs538594407 (C>T) SNPs indicate that they are
predominantly found in subjects with African and European
ancestry (1 and 0.1%, respectively), which is consistent with the
ethnicity information of the subjects identified to carry CC>GT
(Table 1 and Suppl Table 1).
As demonstrated, rs386821512 did not only cause false-
positive results forCYP2D6∗15, but also forCYP2D6∗35. Miscalls
for this allele were initially not detected in the cohort because
the latter was not part of the custom OpenArray panel employed
for genotyping. False-positive calls for CYP2D6∗35, however, are
less consequential because this allele is currently assigned the
same activity score value for phenotype prediction as CYP2D6∗1
(Gaedigk et al., 2008; Hicks et al., 2015). A false-positive result for
31G>A (rs769258) may also be easier to detect than CYP2D6∗15
false-positives, if 2850C>T (rs16947) and 4180G>C (rs1135840)
are part of the test panel. Based on allele definitions, 2850C>T
and 4180G>C are expected to be present if 31G>A is detected
due to complete linkage of these three SNPs in CYP2D6∗35.
This was indeed the case for NA17128, which was negative for
2850C>T and 4180G>C, as well as for −1584G (rs1080985),
which is also part of the CYP2D6∗35 haplotype and may aid in
the identification of false-positives.
After identifying the underlying cause of the false-positive
calls, both TaqMan genotype assays were carefully redesigned
and validated on our sample set. Three of the four sequencing-
confirmed, positives for CYP2D6∗15 samples were correctly
identified, while all false-negative samples returned wild-type
calls. The redesigned assays were also tested on CYP2D7 XL-
PCR template to demonstrate that indeed no signal is produced
from the CYP2D7 GT variant. One sample carrying the 137
T-insertion, however, failed to be detected by the alternative
CYP2D6∗15 TaqMan assay due to the presence of two novel SNPs
within exon 1, which were only discovered during the course of
our investigation. Due to the high sequence similarities between
CYP2D6 and CYP2D7, it appears impossible to steer clear of all
variation when designing genotyping assays. Reliable detection
of CYP2D6∗15 can tentatively only be achieved by a combination
of tests.
Interestingly, we also revealed linkage between the CYP2D7
GT variant and CYP2D6∗43. All samples interrogated for
and shown to carry CC>GT, were initially false-positive for
CYP2D6∗15, and were subsequently heterozygous for 77G>A
(Suppl Table 1). Limited data for CYP2D6∗43 suggest an allele
frequency of about 0.5% (http://www.pharmgkb.org/download.
action?filename=CYP2D6_Frequency_Table_and_Legend_R3.
pdf), which is similar to that reported for rs538594407 and
found in our study cohort (n = 55 including subject 13) which
corresponds to an overall allele frequency of 0.2%, further
supporting linkage between CYP2D7 CC>GT and CYP2D6∗43.
Six samples that were initially false-positive for CYP2D6∗15 and
also had a CYP2D6∗1 allele, did not have 77G>A. Because, these
samples were not interrogated for CYP2D7 CC>GT, however,
we can only speculate whether CYP2D7 CC>GT and 77G>A
are in complete linkage.
One subject (#13, of unknown ethnicity) was tentatively found
to have a novel CYP2D6∗15 subvariant that is characterized by
the presence of two additional CYP2D6 SNPs, 102A>G and
108C>T, both of which correspond to the CYP2D7 reference
sequence (Supplemental Figure 1). Although we were not able
to unequivocally map the two novel SNPs onto the CYP2D6∗15
allele, we infer this location because these SNPs appear to prevent
primer binding of the alternate CYP2D6∗15 assay, causing allele-
drop out. Hence, the assay only detects the wild-type allele on
the other chromosome. We have only identified a single subject
among 13,866, making this allele extremely rare at (0.004%).
In summary, the discovery and systematic characterization
of the underpinning cause of false-positive TaqMan genotyping
assay calls led to the development of alternative CYP2D6∗15
and ∗35 assays to accurately detect these alleles with one caveat,
i.e., a novel, but rare, CYP2D6∗15 subvariant eludes detection
with the alternate assay. Given the sequence similarities between
CYP2D6 and CYP2D7, and polymorphisms each gene harbors
in the region of interest that mimic each other, it is nearly
impossible to design genotyping assays that are CYP2D6-specific,
steer clear of the CYP2D7 CC>GT variation and detect all
CYP2D6∗15 including the novel subvariant. One solution may
be to perform both the initial and alternate assays to identify
true CYP2D6∗15 alleles. In addition, this study also adds valuable
information regarding the frequency of CYP2D6∗15, produced a
complete gene sequence ofCYP2D6∗43, revealed linkage between
CYP2D6∗43 and CYP2D7 CC>GT and, lastly, but not least
important, demonstrates that the presence and variability of a
highly related pseudogene complicates genetic testing of CYP2D6
and can interfere and cause erroneous results.
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